Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
PURPOSE: Infection with COVID-19 potentially can result in severe outcomes and death from "cytokine storm syndrome", resulting in novel coronavirus pneumonia (NCP) with severe dyspnea, acute respiratory distress syndrome (ARDS), fulminant myocarditis and multiorgan dysfunction with or without disseminated intravascular coagulation. No published treatment to date has been shown to adequately control the inflammation and respiratory symptoms associated with COVID-19, apart from oxygen therapy and assisted ventilation. We evaluated the effects of using high dose oral and/or IV glutathione in the treatment of 2 patients with dyspnea secondary to COVID-19 pneumonia. METHODS: Two patients living in New York City (NYC) with a history of Lyme and tick-borne co-infections experienced a cough and dyspnea and demonstrated radiological findings consistent with novel coronavirus pneumonia (NCP). A trial of 2 g of PO or IV glutathione was used in both patients and improved their dyspnea within 1 h of use. Repeated use of both 2000 mg of PO and IV glutathione was effective in further relieving respiratory symptoms. CONCLUSION: Oral and IV glutathione, glutathione precursors (N-acetyl-cysteine) and alpha lipoic acid may represent a novel treatment approach for blocking NF-κB and addressing "cytokine storm syndrome" and respiratory distress in patients with COVID-19 pneumonia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Glutathione Metabolism and Its Implications for Health
Wu, G., Lupton, J. R., Turner, N. D., Fang, Y.-Z., & Yang, S. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.3.489 · Cited by 3,842 · cited 3×
“The first, GCS (gamma-glutamyl-cysteine synthesase (ligase) is rate limiting and normally functions at substantially less than its maximum capacity because of feedback inhibition by GSH, while responding rapidly to GSH requirements [47].”
InfluentialLechien, J. R., Chiesa-Estomba, C. M., De Siati, D. R., Horoi, M., Le Bon, S. D., Rodriguez, A., Dequanter, D., Blecic, S., El Afia, F., Distinguin, L., et al. (2020) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-020-05965-1 · Cited by 2,668 · cited 1×
“Olfactory and gustatory dysfunctions have now been reported as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19) [49].”
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
Zhang, Y., Xiao, M., Zhang, S., Xia, P., Cao, W., Jiang, W., Chen, H., Ding, X., Zhao, H., Zhang, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2007575 · Cited by 2,179 · cited 1×
“A procoagulant effect with coagulopathy and anti-phospholipid antibodies has also recently been reported in patients with COVID-19 [31], associated with a poorer prognosis in patients with novel coronavirus pneumonia (NCP) [32].”
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878 · cited 1×
“Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription [72], and both curcumin and sulforaphane are potent Nrf2 activators that have been shown to decrease a broad range of inflammatory cytokines including IL-6 [73], helping to lower inflammation [74,75].”
Zinc and immune function: the biological basis of altered resistance to infection
Shankar, A. H., & Prasad, A. S. (1998) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/68.2.447s · Cited by 1,606 · cited 2×
“Zinc is known to play a central role in the immune system, and zinc-deficient persons experience increased susceptibility to a variety of pathogens [62].”
COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features
Poyiadji, N., Shahin, G., Noujaim, D., Stone, M., Patel, S., & Griffith, B. (2020) · Radiology · doi:10.1148/radiol.2020201187 · Cited by 1,505
Cited by
COVID-19: Hemoglobin, Iron, and Hypoxia beyond Inflammation. A Narrative Review
Cavezzi, A., Troiani, E., & Corrao, S. (2020) · Clinics and Practice · doi:10.4081/cp.2020.1271 · Cited by 430
SARS-CoV-2 infection pathogenesis is related to oxidative stress as a response to aggression
Cecchini, R., & Cecchini, A. L. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110102 · Cited by 399
Polonikov, A. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00288 · Cited by 273
Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome
Paul, B. D., Lemle, M. D., Komaroff, A. L., & Snyder, S. H. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024358118 · Cited by 267
Alexander, J., Tinkov, A., Strand, T. A., Alehagen, U., Skalny, A., & Aaseth, J. (2020) · Nutrients · doi:10.3390/nu12082358 · Cited by 249
“Administration of glutathione has been shown to relieve dyspnea associated with COVID-19 pneumonia [70].”
BackgroundHamidi, S. H., Kadamboor Veethil, S., & Hamidi, S. H. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00255-x · Cited by 50
Metadata
- Authors
- Horowitz, R. I., Freeman, P. R., & Bruzzese, J.
- Venue
- Respiratory Medicine Case Reports
- Publisher
- Elsevier BV
- Published
- 2020
- Volume
- 30
- Pages
- 101063
- ISSN
- 2213-0071 (ISSN-L)
- OpenAlex
- W3020401968
- Cited by
- 181
- References
- 16
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.